News and Announcements
OncoSil Medical Limited recruits for Global Pancreatic Clinical Study Programme
- Published March 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX:OSL) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce to Monash Health has recruited the first subject for its global clinical study program in pancreatic cancer.
The first subject has completed all baseline assessments and will now commence one month of chemotherapy prior to implantation with OncoSil™ device.
KEY TAKEAWAYS:
- First subject recruited for global clinical study in pancreatic cancer by Monash Health, Melbourne.
- This subject is the first in a total of 20 subjects required to meet the Supplemental data request to secure CE Marking.
- Company well positioned to provide supplemental data, with 16 leading centres confirming participation in the clinical programme.
- St Vincent’s hospital, Sydney received Ethics approval on 16 March to participate in the global study.
Monash Health is the largest public health service in Melbourne, and has agreed to be the lead Australian study centre. It provides health care services to more than 1.5 million people. All cancer treatments are provided through the Monash Cancer Centre, one of Victoria’s premier cancer facilities.
This patient is the first in a total of 20 subjects required to meet the supplemental data request from BSI, the Company’s Notified Body to secure CE Marking for the OncoSil™ device. The Company is very well positioned to provide the supplemental data from its clinical study programme. To date, OncoSil Medical has confirmed the participation of 16 centres for its global pancreatic clinical study programme.
One of these centres, St Vincent’s Hospital, Sydney received Ethics approval on 16 March and is expected to commence recruiting subjects for the study programme in the coming weeks.
OncoSil Medical is working with large recruitment centres, and many of the sites included in the study are top-tier cancer centres, including MD Anderson and John Hopkins in the US.
OncoSil Chief Executive Officer, Daniel Kenny commented:
“We are pleased to report that the first subject for our global pancreatic clinical programme was recruited from our lead Australian site, Monash Health. The data from this subject and 19 others to be recruited from tier-one centres in the US, UK and other Australian centres will contribute to our supplemental data request for CE Marking. We look forward to updating the market with our recruitment progress over the coming weeks.”
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
